-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $36

Benzinga·05/26/2026 10:57:24
Listen to the news
Goldman Sachs analyst Richard Law initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $36.